Skip to main content

Lidocaine Dosage

Medically reviewed by Drugs.com. Last updated on Sep 29, 2023.

Applies to the following strengths: 2%; 1%; 1.5%; 1% preservative-free; 0.5%; 4%; 7.5%-5%; 20%; 10%; 5%-0.2%; 5%-0.4%; 5%-0.8%; 2% preservative-free; 1.5% preservative-free; 0.5% preservative-free; 4% preservative-free; 5%; hydrochloride; 1%-NaCl 0.9%; buffered 0.9% preservative-free; buffered 1% preservative-free; 1%-NaCl 0.7% preservative-free; 2%-NaCl 0.48% preservative-free

Usual Adult Dose for Ventricular Fibrillation

Initial dose: 50 to 100 mg IV bolus once over 2 to 3 minutes; may repeat after 5 minutes if necessary not to exceed up to 300 mg in a 1-hour period
Following bolus administration: 1 to 4 mg/min continuous IV infusion

Comments:


Uses: For the acute management of ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery; and for life-threatening arrhythmias which are ventricular in origin, such as those that occur during acute myocardial infarction

The American Heart Association (AHA) recommends:
IV:

Endotracheal: May be administered endotracheally (bolus dose only) if IV access unavailable at a dose of 2 to 2.5 times the IV dose diluted in 5 to 10 mL NS or distilled water

Uses: For the treatment of ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) unresponsive to CPR, defibrillation, and vasopressor therapy as an alternative to amiodarone

Usual Adult Dose for Ventricular Tachycardia

Initial dose: 50 to 100 mg IV bolus once over 2 to 3 minutes; may repeat after 5 minutes if necessary not to exceed up to 300 mg in a 1-hour period
Following bolus administration: 1 to 4 mg/min continuous IV infusion

Comments:


Uses: For the acute management of ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery; and for life-threatening arrhythmias which are ventricular in origin, such as those that occur during acute myocardial infarction

The American Heart Association (AHA) recommends:
IV:

Endotracheal: May be administered endotracheally (bolus dose only) if IV access unavailable at a dose of 2 to 2.5 times the IV dose diluted in 5 to 10 mL NS or distilled water

Uses: For the treatment of ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) unresponsive to CPR, defibrillation, and vasopressor therapy as an alternative to amiodarone

Usual Adult Dose for Cardiac Arrhythmia

Initial dose: 50 to 100 mg IV bolus once over 2 to 3 minutes; may repeat after 5 minutes if necessary not to exceed up to 300 mg in a 1-hour period
Following bolus administration: 1 to 4 mg/min continuous IV infusion

Comments:


Uses: For the acute management of ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery; and for life-threatening arrhythmias which are ventricular in origin, such as those that occur during acute myocardial infarction

The American Heart Association (AHA) recommends:
IV:

Endotracheal: May be administered endotracheally (bolus dose only) if IV access unavailable at a dose of 2 to 2.5 times the IV dose diluted in 5 to 10 mL NS or distilled water

Uses: For the treatment of ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT) unresponsive to CPR, defibrillation, and vasopressor therapy as an alternative to amiodarone

Usual Adult Dose for Anesthesia

Local Injectable Anesthesia:


Comments:

Use: For the production of local or regional anesthesia by infiltration techniques such as percutaneous injection and IV regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed

Usual Pediatric Dose for Ventricular Fibrillation

The manufacturer gives no specific dosing instructions.

The AHA recommends:
IV:


Endotracheal: May be administered endotracheally (bolus dose only) if IV or intraosseous access unavailable at a dose of 2 to 3 times the dose (2 to 3 mg/kg) followed by a flush with at least 5 mL of NS and 5 consecutive positive-pressure ventilations

Use: For use in shock-refractory VF or pVT after resuscitation from cardiac arrest in infants and children

Usual Pediatric Dose for Ventricular Tachycardia

The manufacturer gives no specific dosing instructions.

The AHA recommends:
IV:


Endotracheal: May be administered endotracheally (bolus dose only) if IV or intraosseous access unavailable at a dose of 2 to 3 times the dose (2 to 3 mg/kg) followed by a flush with at least 5 mL of NS and 5 consecutive positive-pressure ventilations

Use: For use in shock-refractory VF or pVT after resuscitation from cardiac arrest in infants and children

Usual Pediatric Dose for Anesthesia

3 years or older with normal lean body mass and normal body development: Maximum dose based on patient's age and weight

Comments:


Use: For the production of local or regional anesthesia by infiltration techniques such as percutaneous injection and IV regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed

Renal Dose Adjustments

Use with caution; renal dysfunction may increase the accumulation of metabolites, leading to toxicity.

Liver Dose Adjustments

Patients with reduced hepatic function or diminished hepatic blood flow should receive half the usual loading dose and lower maintenance doses IV:
Adult:


Pediatric: Data not available

Dose Adjustments

Dosages should be reduced for children, the elderly, and debilitated patients and those with cardiac and/or liver disease.

Patients with shock, congestive heart failure, or cardiac arrest:

Precautions

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

Monitoring:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.